 Carbazoles
"Carbazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Benzo-indoles similar to CARBOLINES which are pyrido-indoles. In plants, carbazoles are derived from indole and form some of the INDOLE ALKALOIDS.
| Descriptor ID |
D002227
|
| MeSH Number(s) |
D03.633.100.473.144 D03.633.300.148
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Carbazoles".
Below are MeSH descriptors whose meaning is more specific than "Carbazoles".
This graph shows the total number of publications written about "Carbazoles" by people in this website by year, and whether "Carbazoles" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 | | 1996 | 6 | 0 | 6 | | 1997 | 2 | 0 | 2 | | 1998 | 1 | 1 | 2 | | 1999 | 3 | 0 | 3 | | 2000 | 1 | 3 | 4 | | 2001 | 5 | 1 | 6 | | 2002 | 0 | 4 | 4 | | 2003 | 1 | 1 | 2 | | 2004 | 2 | 0 | 2 | | 2005 | 2 | 0 | 2 | | 2006 | 0 | 1 | 1 | | 2008 | 2 | 1 | 3 | | 2009 | 1 | 0 | 1 | | 2010 | 2 | 1 | 3 | | 2011 | 2 | 0 | 2 | | 2012 | 1 | 0 | 1 | | 2014 | 0 | 2 | 2 | | 2015 | 7 | 1 | 8 | | 2016 | 2 | 0 | 2 | | 2017 | 2 | 0 | 2 | | 2018 | 1 | 0 | 1 | | 2019 | 0 | 2 | 2 | | 2020 | 0 | 1 | 1 | | 2021 | 3 | 0 | 3 | | 2022 | 0 | 3 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Carbazoles" by people in Profiles.
-
Reckamp KL, Lin HM, Cranmer H, Wu Y, Zhang P, Kay S, Walton LJ, Shen J, Popat S, Camidge DR. Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase-positive non-small cell lung cancer using data from ALEX and final results from ALTA-1L. Curr Med Res Opin. 2022 09; 38(9):1587-1593.
-
Reckamp KL, Lin HM, Cranmer H, Wu Y, Zhang P, Walton LJ, Kay S, Cichewicz A, Neupane B, Fahrbach K, Popat S, Camidge DR. Indirect comparisons of brigatinib and alectinib for front-line ALK-positive non-small-cell lung cancer. Future Oncol. 2022 Jun; 18(20):2499-2510.
-
Dziadziuszko R, Peters S, Mok T, Camidge DR, Gadgeel SM, Ou SI, Konopa K, No? J, Nowicka M, Bordogna W, Morcos PN, Smoljanovic V, Shaw AT. Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX Trial. Clin Cancer Res. 2022 05 02; 28(9):1800-1808.
-
Tsui DCC, Aisner D, Nijmeh H, Bao L, Menter A, Camidge DR. Tumor Shrinkage With Combination of Alectinib and Trastuzumab in a Patient With ALK-Rearranged Non-small Cell Lung Cancer Harboring HER2-Amplification as an Acquired Resistance Mechanism to ALK Inhibitor Therapy. Clin Lung Cancer. 2022 03; 23(2):e99-e103.
-
Ji J, Mitra A, Camidge DR, Riess JW. Early Alectinib Resistance From MET Amplification in ALK-Rearranged NSCLC: Response to Crizotinib with Re-Response to Alectinib and Crizotinib. Clin Lung Cancer. 2021 11; 22(6):e851-e855.
-
Brown PA, Kairalla JA, Hilden JM, Dreyer ZE, Carroll AJ, Heerema NA, Wang C, Devidas M, Gore L, Salzer WL, Winick NJ, Carroll WL, Raetz EA, Borowitz MJ, Small D, Loh ML, Hunger SP. FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631. Leukemia. 2021 05; 35(5):1279-1290.
-
Yao Q, The E, Ao L, Zhai Y, Osterholt MK, Fullerton DA, Meng X. TLR4 Stimulation Promotes Human AVIC Fibrogenic Activity through Upregulation of Neurotrophin 3 Production. Int J Mol Sci. 2020 Feb 14; 21(4).
-
Camidge DR, Dziadziuszko R. Authors' Reply. J Thorac Oncol. 2019 09; 14(9):e196-e197.
-
Camidge DR, Dziadziuszko R, Peters S, Mok T, Noe J, Nowicka M, Gadgeel SM, Cheema P, Pavlakis N, de Marinis F, Cho BC, Zhang L, Moro-Sibilot D, Liu T, Bordogna W, Balas B, M?ller B, Shaw AT. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib?in?Untreated ALK-Positive Advanced Non-Small Cell?Lung Cancer in the Global Phase III ALEX Study. J Thorac Oncol. 2019 07; 14(7):1233-1243.
-
Gadgeel S, Peters S, Mok T, Shaw AT, Kim DW, Ou SI, P?rol M, Wrona A, Novello S, Rosell R, Zeaiter A, Liu T, N?esch E, Balas B, Camidge DR. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. Ann Oncol. 2018 11 01; 29(11):2214-2222.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|